Concord Biotech share price prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
- June 18, 2026
- Posted by: Kunal Singla
- Category: News
Concord Biotech (NSE:CONCORDBIO) CMP: Rs 1,360 (2026). 52W High: Rs 2,083. 52W Low: Rs 987. MCap: Rs 14,222 Cr. P/E: 53.5. Sector: Pharmaceuticals and Healthcare. JM Financial: Buy Rs 1600. ICICI S…
The Concord Biotech share price prediction for 2026 from leading brokerages covers a range reflecting sector dynamics, earnings trajectory and the macro environment. All estimates may or may not be achieved. Treat any Concord Biotech share price prediction as one data point and not as a guarantee of future performance.
This article reviews every dimension of the Concord Biotech stock forecast analysts are tracking, including key drivers, bull and bear scenarios and the primary risks. Verify all figures with the latest brokerage reports before any investment decision.
Click Here – Get Free Investment Predictions
What Analysts Predict for Concord Biotech Stock in 2026
Analyst consensus on the Concord Biotech share price prediction for 2026 is tracked by leading brokerages. The table below shows the latest available data from JM Financial and ICICI Securities. All figures are sourced from publicly available research and should be verified before publishing.
| Brokerage | Rating | Concord Biotech share price prediction (Rs) | Updated |
|---|---|---|---|
| JM Financial | Buy | Rs 1600 | 2026 |
| ICICI Securities | Neutral | Rs 1480 | 2026 |
| Analyst Consensus | — | Rs 1540 | 2026 |
The analyst target range for Concord Biotech reflects genuine difference of opinion on demand recovery, margin trajectory and sector headwinds. The implied upside in the Concord Biotech stock forecast from the current price of Rs 1,360 may or may not be realised by end of 2026.
3 Stocks Building Serious Momentum Right Now
When Univest analysts identify high-conviction stock opportunities, investors pay attention.
Our research team has shortlisted the Top Stocks to Buy based on current market momentum, sector trends & growth potential for 2026.
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Unlock the latest Top Stock Picks now on Univest
Concord Biotech Company Overview
Concord Biotech is a significant player in India’s pharmaceutical industry with a presence across domestic formulations, US generics and specialty segments. The Concord Biotech share price prediction for 2026 reflects both the pipeline growth potential and regulatory risk.
| Metric | Value |
|---|---|
| NSE Ticker | CONCORDBIO |
| Sector | Pharmaceuticals and Healthcare |
| CMP | Rs 1,360 (2026) |
| 52 Week High | Rs 2,083 |
| 52 Week Low | Rs 987 |
| Market Cap | Rs 14,222 Cr |
| P/E Ratio | 53.5 |
| Concord Biotech share price prediction Consensus (12M) | Rs 1540 |
Concord Biotech share price prediction by Time Horizon
Analysts split the Concord Biotech share price prediction across time frames as near-term drivers differ materially from the long-term view.
Short-Term Concord Biotech share price prediction
The near-term Concord Biotech stock forecast reflects current sentiment, sector news and upcoming earnings prints. Key support and resistance levels around Rs 1,360 are being watched closely. A short-term Concord Biotech share price prediction carries the most uncertainty of any time horizon.
12-Month Concord Biotech share price prediction
JM Financial targets Rs 1600 (Buy) and ICICI Securities targets Rs 1480 (Neutral). Most desks refresh their Concord Biotech stock forecast within two to four weeks of each quarterly earnings print. The Concord Biotech share price prediction should be verified against the most recent analyst reports.
Long-Term Concord Biotech share price prediction
The long-term outlook for Concord Biotech is built on assumptions about demand recovery, margin expansion and revenue diversification in the Pharmaceuticals and Healthcare sector. Long-term price targets carry the most uncertainty and should be treated as directional guidance only.
Concord Biotech Stock Forecast: Key Factors
The following four factors appear consistently in analyst research on Concord Biotech and are the primary inputs into the bull and bear case scenarios.
US Generic Revenue
US generics revenue is the most watched metric in the Concord Biotech stock forecast. USFDA approval timelines and price erosion rates directly affect the Concord Biotech share price prediction from most research desks.
Domestic Formulations Growth
Domestic formulation growth provides a stable base that supports the Concord Biotech share price prediction even when export growth faces headwinds.
R&D Pipeline
The depth and commercialization pace of the R&D pipeline is a key variable in the long-term Concord Biotech share price prediction. New product approvals are cited as catalysts for the Concord Biotech share price prediction.
EBITDA Margin
Sustained EBITDA margin expansion is typically the basis for the bullish Concord Biotech stock forecast. Margin recovery strengthens the Concord Biotech share price prediction from most research desks.
Concord Biotech share price prediction: Bull and Bear Scenarios
| Scenario | Concord Biotech share price prediction | Key Conditions |
|---|---|---|
| Bull Case | Rs 1600 | Strong execution, margin improvement, favourable macro and sector re-rating |
| Base Case | Rs 1540 | Steady performance, gradual recovery, margins hold, growth on track |
| Bear Case | Rs 987 | Demand deterioration, margin pressure, sector de-rating and macro headwinds |
The bull case Concord Biotech stock forecast of Rs 1600 assumes most positive variables converge. The base case of Rs 1540 is the analyst consensus and may or may not be achieved.
How Analysts Are Reading the Concord Biotech Stock Story
Analyst reviews of the Concord Biotech share price prediction highlight the company’s core strengths in Pharmaceuticals and Healthcare alongside near-term headwinds from macro uncertainty, competitive pressure and sector-level challenges. Overall the analyst consensus for Concord Biotech is built on real business strengths set against real risks.
Key Risks to the Concord Biotech share price prediction
USFDA Regulatory Risk
Import alerts and warning letters from the USFDA are the most significant risks to the Concord Biotech share price prediction. A facility closure would force an immediate sharp revision to the Concord Biotech share price prediction.
Price Erosion in the US
Pricing pressure in US generics compresses the revenue per product and affects the Concord Biotech stock forecast. Aggressive price erosion pushes the Concord Biotech share price prediction toward the bear case.
R&D Execution Risk
Delays in clinical trials or approval failures affect the Concord Biotech share price prediction. The Concord Biotech share price prediction is particularly sensitive to key pipeline asset announcements.
Currency Risk
A strengthening rupee against the dollar reduces export realisation and affects the Concord Biotech stock forecast. Currency risk is embedded in conservative Concord Biotech share price prediction models.
How to Monitor the Concord Biotech Stock Forecast
Track the Concord Biotech share price prediction consensus quarterly. After every earnings release, most brokerages revise their Concord Biotech stock forecast within two weeks. Comparing the revised analyst target to the previous estimate tells you whether sentiment on Concord Biotech is improving or deteriorating.
Compare the current price of Rs 1,360 with the analyst target range of Rs 1600 to Rs 1480. A wide target band reflects genuine uncertainty on Concord Biotech, so position size should reflect that range rather than the midpoint alone.
Review the Concord Biotech share price prediction every quarter against key business metrics for the Pharmaceuticals and Healthcare sector. A single estimate from any analyst is a point-in-time view and should be treated as one input among many when making any investment decision.
Check Live Concord Biotech Fundamentals on the Univest Screener
Conclusion
The Concord Biotech share price prediction for 2026 reflects the analyst community’s assessment of Concord Biotech’s competitive position, earnings trajectory and macro environment. JM Financial holds a Buy stance with a target of Rs 1600 while ICICI Securities has a Neutral rating with a target of Rs 1480, giving an analyst consensus of Rs 1540.
The Concord Biotech stock forecast is set against near-term risks that make the Concord Biotech share price prediction range wide. Investors should verify any estimate with the latest brokerage reports before using it as an investment reference. The analyst forecast will be revised after every quarterly result, so tracking how the Concord Biotech share price target changes over time is more valuable than relying on any single estimate.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.
Download the Univest iOS App or Univest Android App to track live analyst targets, price movements and research updates for Concord Biotech in real time.
Disclaimer: Data and figures in this article are sourced from publicly available information and may or may not be accurate. Analyst price targets are from public brokerage reports and should be independently verified. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Concord Biotech share price prediction 2026
What is the Concord Biotech share price prediction for 2026?
Ans. The Concord Biotech share price prediction for 2026 is based on analyst consensus from JM Financial and ICICI Securities. The consensus target is Rs 1540. All estimates may or may not be achieved.
Is the Concord Biotech share price prediction bullish or bearish?
Ans. JM Financial has a Buy rating with target Rs 1600. ICICI Securities has a Neutral rating with target Rs 1480. The Concord Biotech stock forecast reflects genuine analyst diversity of opinion.
What is the Concord Biotech share price prediction based on fundamentals?
Ans. The Concord Biotech share price prediction rests on the US generic pipeline, domestic growth, EBITDA margin and regulatory compliance track record. Analysts tracking Concord Biotech closely cite these as the primary drivers of the 2026 outlook.
What is the long-term Concord Biotech share price prediction?
Ans. The long-term outlook assumes Concord Biotech sustains its core business drivers over a multi-year horizon. The 12-month consensus of Rs 1540 is the nearest reliable anchor point.
What are the key risks to the Concord Biotech share price prediction?
Ans. The primary risks include sector-specific headwinds, macro uncertainty, regulatory changes and competitive pressure. Every analyst estimate for Concord Biotech should be read alongside its risk assumptions.
What does the Concord Biotech stock forecast say for 2026?
Ans. JM Financial: Buy target Rs 1600. ICICI Securities: Neutral target Rs 1480. These Concord Biotech share price prediction estimates may or may not prove accurate.
Where can I track the latest Concord Biotech share price prediction?
Ans. Track the latest analyst targets and price movements for Concord Biotech on the NSE and BSE websites and on the Univest app and screener for live data.
